Novavax executives' pay comes back down to Earth after 8-figure package in 2020 Astellas takes $170M hit as DMD gene therapy plan unravels in wake of preclinical data Bayer nabs yet another oncology leader from GSK to bolster cancer efforts Sponsored: CDx Biomarkers for Oncology Research & Development The Clever-1? Faron hails melanoma data despite lack of responses Vallon looks for escape route a month after sole clinical asset fails in clinic Reify raises $220M to bridge trial diversity gaps, setting valuation at $4.8B Global trust in pharma CEOs in the doldrums when it comes to 'telling the truth about health' White House pushes for more money for harm reduction in drug control strategy plan Genentech-led team uncovers how cancer cells resist T-cell attack in potential boon to immunotherapy WHO gives a thumbs up to Pfizer's Paxlovid while scolding the company for its 'lack of price transparency' Intuitive Surgical pulls off 15% revenue growth despite ongoing COVID, supply chain challenges Regeneron CEO's pay drops 95%—but that shouldn't come as a shock Chutes & Ladders—Romanelli returns to Merck to lead international human health team after brief CEO stint Fierce Pharma Asia—Merck's Romanelli returns; Sanofi's 'factory of the future'; Fujifilm's $450M contract Featured Story | By Annalee Armstrong,Max Bayer 2020 was a good year for Novavax’s executives, who were showered with eight-figure pay packages. For 2021, the cash has dropped down, but thanks to some accounting changes, it sounds like 2022 might see another big payday for the vaccine maker's top brass. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Astellas’ gene therapy strategy is sinking deeper into the mire. Having reviewed the data on its Duchenne muscular dystrophy (DMD) therapies, the Japanese drugmaker has decided to scrap the candidates, triggering a $170 million impairment loss. read more By Gabrielle Masson For the second time this year, German drugmaker Bayer has nabbed an oncology leader from GlaxoSmithKline, appointing Tara Frenkl, M.D., to lead oncology development for its oncology strategic business unit. read more Sponsored by: Precision for Medicine Biomarker discovery and development are critical for advancing oncology therapeutics and informing patient management. Experts discuss evaluating biomarkers in drug-diagnostic co-development programs. read more By Nick Paul Taylor Faron Pharmaceuticals has posted data on its tumor-associated macrophage candidate bexmarilimab, linking the antibody to one unconfirmed partial response in a cohort of 11 checkpoint inhibitor refractory melanoma patients. read more By Max Bayer A month after Vallon Pharmaceuticals' one and only clinical-stage asset failed its first phase 1 test, the company is looking for an escape route to save the business. Vallon has tapped a law firm and investment bank to help with a strategic review, with the goal of finding any and all opportunities to stay afloat. read more By Gareth Macdonald Reify Health says $220 million in new funding round will support development of its diversity-focused clinical trial recruitment technologies and initiatives. read more By Ben Adams Pharmaceutical chiefs are among the least trusted group of people when it comes to talking about health. That’s the damning finding from a new report from consultants Edelman, which found that just 46% of those surveyed trusted CEOs of healthcare companies, on par with government leaders but well below a patient’s doctor at 76%. read more By Robert King The White House unveiled a new national drug control strategy that for the first time touts harm reduction strategies such as supervised syringe sites. read more By Angus Liu Cancer cells deploy various tactics to avoid being targeted and killed by the immune system. A research team led by Roche’s Genentech has now identified one such method that cancer cells use to resist T-cell assault by repairing damage. read more By Kevin Dunleavy In recommending the use of Pfizer's COVID-19 oral antiviral, Paxlovid, for at-risk patients with mild-to-moderate COVID, the World Health Organization also implored the company to make the treatment more readily accessible to the world. read more By Andrea Park The year-over-year growth stemmed from a 19% surge in the number of procedures performed around the world using Intuitive’s da Vinci robotic surgery system. read more By Fraiser Kansteiner Regeneron's CEO, Leonard Schleifer, M.D., Ph.D., collected a total of $6.47 million in 2021 pay, a whopping 95% decrease from the $135 million he made the year before. The compensation slump was to be expected, however. read more By Max Bayer Joseph Romanelli is returning to his roots, rejoining Merck to lead the company's international human health business. Bayer taps former GSK leader Frenkl to help chart the course of its oncology program. Fore names Ros as its new CEO nearly five months after ousting its former leader over insider trading charges. read more By Angus Liu Merck's former China head will return to the Big Pharma to lead international human health. Sanofi has kicked off construction of a new vaccine production plant in Singapore. Fujifilm secured a $450 million contract with the U.S. government for its endoscopy technologies. And more. read more Resources Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Cancer Progress 2022: Hear from Leading Oncology Innovators May 10-12, 2022 | Virtual Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Live & Recorded on: Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Free Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 